U.S. Venture Partners
VC Fund
Menlo Park, United States
U.S. Venture Partners (USVP) is a venture capital partnership, helping entrepreneurs transform their ideas and efforts into world-changing companies. The firm focuses on early-stage ventures in information technology and health care, where innovation is unbridled and has led to the creation of economic wealth and millions of jobs over the past thirty-plus years of the firm's existence. Areas of particular interest to our investment professionals include enterprise software, IT security, consumer internet, mobile, and e-commerce, healthcare, and IT-enabled healthcare services. The USVP team consists of former entrepreneurs, technologists, corporate executives, financial professionals, and industry domain experts.
- Total investments:
- 475
- Last investment:
- Lead investor:
- 33%
- Fund size:
- $400M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries U.S. Venture Partners invests in
Stages U.S. Venture Partners invests in
Countries U.S. Venture Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 9 contacts → | |||
Round size
- Series A
- $5M–$40M
- Series B
- $6.8M–$50M
- Series C
- $8M–$68M
Investment Focus
Industry
- Software 62 (13%)
- Health Care 56 (12%)
- Information Technology 33 (7%)
- Medical 31 (7%)
- Medical Device 29 (6%)
Stage
- Series B 111 (23%)
- Series C 84 (18%)
- Series A 73 (15%)
- Funding Round 43 (9%)
- Series D 41 (9%)
Country
- United States 211 (44%)
- Israel 13 (3%)
- Canada 4 (1%)
- France 2 (0%)
- China 1 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Phil Young
Senior Advisor
|
Senior Advisor | Total investments: 10 | Find email | |
Casey Tansey
General Partner
|
General Partner | Total investments: 29 | Find email | |
Dafina Toncheva
General Partner
|
General Partner | Total investments: 39 | Find email | |
Dale Holladay
CPA/CFO
|
CPA/CFO | Total investments: 0 | Find email | |
Jacques Benkoski
General Partner
|
General Partner | Total investments: 27 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| HighLife is a company focused on Transcatheter Mitral Valve Replacement (TMVR). The technology is intended for treatment of patients suffering from mitral valve regurgitation and is currently in a stage of clinical evaluation.The company was co-founded in 2010 by Mr. Georg Börtlein, President & CEO. The intent is to provide a minimallyinvasive prosthetic mitral valve that is implanted on a beating heart, while preserving the native valve structure and respecting the surrounding anatomy. Ease and safety of use and delivery are key elements of the HighLife technology. | $90M / Venture - Series Unknown / Sep 22, 2026 | ||
| ReEmerge is a medical technology company that develops Cognitive Network Restoration Therapy, a neurostimulation approach designed to address chronic cognitive impairment following brain injury. Its technology uses targeted electrical stimulation of neural networks to activate underperforming but viable brain circuits, with the goal of improving cognitive function and supporting recovery in patients with persistent impairments. | $37M / Series A / Sep 15, 2026 | ||
| Maneva develops video-to-action artificial intelligence systems for manufacturing environments, using computer vision and deep learning to analyze production processes and support operational decision-making in real time. Its platform helps manufacturers address quality assurance, downtime reduction, productivity monitoring, and workplace safety byconverting visual data from factory-floor cameras into actionable insights and automated responses. The company offers solutions such as VITA for defect detection, product verification, and equipment monitoring, as well as ALIS, an AI-powered line supervision system that tracks production efficiency and safety compliance. Maneva's technology is designed to work with existing camera infrastructure and can be applied across industries, including food and beverage, pharmaceuticals, electronics, automotive, steel, and distribution operations. The company focuses on helping manufacturers improve production consistency, identify operational issues, and monitor factory processes through AI-driven visual analysis. | $27M / Series A / Jun 10, 2026 | ||
| Cagent Vascular is a medical device company developing minimally invasive technologies to treat cardiovascular disease. | $41M / Series D / May 19, 2026 | ||
| Nervonik is a medical device company developing an opioid-free peripheral nerve stimulation (PNS) system. Nervonik is focused on advancing clinical research and achieving regulatory milestones to bring its innovative therapies to market. | $52.5M / Series B / Apr 27, 2026 | ||
| Route 92 Medical is a developer of a stealthy catheter for stroke treatment. The company was founded in 2015 and based in San Mateo, California. | $50M / Private Equity / Apr 07, 2026 | ||
| Slang.ai is a digital phone concierge that answers questions, takes reservations, and satisfies callers. | $28M / Series B / Feb 24, 2026 | ||
| Adaptive6 is a Cloud Cost Governance platform that addresses both cloud and code, providing a comprehensive approach to managing costs effectively. The platform empowers engineers to take immediate action on cloud costs and prevents waste at the code level, enhancing efficiency in cloud management. | $28M / Series A / Jan 28, 2026 | ||
| Okami Medical develops and commercializes new devices for the treatment of heart disease. It was formed to address the evolving needs of patients and physicians through the development of innovative, versatile, and intuitive medical devices for the occlusion of peripheral vessels. Okami believes that vessel occlusion should be rapid and reliableregardless of tortuosity and flow conditions. The LOBO Vascular Occlusion System was developed for this reason.It was founded in 2011 and is headquartered in Aliso Viejo, California. | $45M / Series F / Nov 19, 2025 | ||
| Apono helps companies become secure and compliant while maintaining their productivity and agility. The company aims to simplify how teams manage access to critical systems by automating the provisioning and deprovisioning of permissions based on real-time needs, ensuring only the right people have access at the right time. | $34M / Series B / Nov 18, 2025 | ||
| See all 475 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does U.S. Venture Partners invest in?
U.S. Venture Partners invests primarily in Software, Health Care and Information Technology startups, most often at Series B and Series C stage. Most of the 475 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does U.S. Venture Partners invest in?
U.S. Venture Partners typically joins rounds of $5M–$40M at Series A, $6.8M–$50M at Series B and $8M–$68M at Series C. These are whole funding-round sizes, not U.S. Venture Partners's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds U.S. Venture Partners took part in.
How do I contact U.S. Venture Partners?
Public channels for U.S. Venture Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at U.S. Venture Partners?
The team at U.S. Venture Partners includes Phil Young (Senior Advisor), Casey Tansey (General Partner) and Dafina Toncheva (General Partner), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
